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Aim

Obstructive coronary artery disease (CAD) in proximal coronary segments is associated with a poor prognosis.
However, the relative importance of plaque location regarding the risk for major adverse cardiovascular events
(MACE) in patients with non-obstructive CAD has not been well defined.

...................................................................................................................................................................................................
Methods
From the Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter (CONFIRM)
registry, 4644 patients without obstructive CAD were included in this study. The degree of stenosis was classified
and results

as 0 (no) and 1–49% (non-obstructive). Proximal involvement was defined as any plaque present in the left main or
the proximal segment of the left anterior descending artery, left circumflex artery, and right coronary artery.
Extensive CAD was defined as segment involvement score of >4. During a median follow-up of 5.2 years (interquartile range 4.1–6.0), 340 (7.3%) MACE occurred. Within the non-obstructive CAD group (n = 2065), proximal
involvement was observed in 1767 (85.6%) cases. When compared to non-obstructive CAD patients without proximal involvement, those with proximal involvement had an increased MACE risk (log-rank P = 0.033). Multivariate
Cox analysis showed when compared to patients with no CAD, proximal non-obstructive CAD was associated
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with increased MACE risk [hazard ratio (HR) 1.90, 95% confidence interval (CI) 1.47–2.45, P < 0.001] after adjusting
for extensive CAD and conventional cardiovascular risk factors; however, non-proximal non-obstructive CAD did
not increase MACE risk (HR 1.26, 95% CI 0.79–2.01, P = 0.339).
with non-obstructive CAD. The plaque location information by coronary computed tomography angiography may
provide additional risk prediction over CAD extent in patients with non-obstructive CAD.
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Graphical Abstract
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Keywords
coronary artery disease • non-obstructive • plaque location • prognosis • computed tomography

Downloaded from https://academic.oup.com/ehjcimaging/advance-article/doi/10.1093/ehjci/jeab223/6428082 by Henry Ford Hospital user on 16 December 2021

...................................................................................................................................................................................................
Conclusions
Independent of plaque extent, proximal coronary involvement was associated with increased MACE risk in patients
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Introduction

Figure 1 Study flow. CAD, coronary artery disease; CCTA, coronary computed tomography angiograpy; LAD, left anterior descending artery;
LCX, left circumflex artery; LM, left main; RCA, right coronary artery.
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Coronary computed tomography angiography (CCTA) is a noninvasive imaging technique that allows for accurate detection and
assessment of coronary artery disease (CAD).1,2 One feature of
CAD evaluation by CCTA is that it provides information on the
presence, quantity, and distribution of non-obstructive coronary
atherosclerotic lesions. Previous studies reported that a significant
proportion of patients, up to 70%, who underwent CCTA were
found to have non-obstructive CAD.3–5 Presence of non-obstructive CAD by CCTA is associated with increased future major adverse cardiovascular events (MACE) when compared to the
absence of CAD on CCTA.5–8
Findings from early angiographic studies suggested that proximally
located atherosclerotic plaques are at higher risk of erosion or
rupture with the consequence of acute coronary events.9,10
Furthermore, proximal vessels supply larger portions of the myocardium, and the occurrence of acute coronary events in proximal
vessels is more likely to lead to a clinically significant event. Although
the incidence of cardiovascular events is associated with stenosis
severity, a substantial proportion of cardiac events arise from nonobstructive coronary lesions.11–13 While the prognostic significance
of proximally located plaque in obstructive CAD by CCTA is well

.. established,4,14–16 the contribution of proximal plaque location to
..
.. MACE in patients with non-obstructive CAD is not fully defined. In
.. an international multicentre CCTA registry, we examined MACE risk
..
.. in relation to the location of non-obstructive coronary artery plaque
..
.. by CCTA.
..
..
..
.. Methods
..
..
.. Study population
.. The Coronary CT Angiography Evaluation for Clinical Outcomes: An
..
.. International Multicenter (CONFIRM) registry is a dynamic, international,
.. multicentre, observational cohort study designed to evaluate the associ..
.. ation between patient characteristics, CCTA findings, and adverse clinical
.. events. In total, 17 181 patients had been enrolled between February
..
.. 2003 and May 2011 and underwent CCTA at 17 centres located in nine
.. countries (Austria, Canada, Germany, Israel, Italy, Portugal, South Korea,
..
.. Switzerland, and USA). Details of the rationale and design of the
.. CONFIRM registry have been described previously.17 In the current
..
.. study, we excluded patients with incomplete adjudication of clinical
.. events (n = 7914), missing stenosis severity information (n = 440), missing
.. plaque location information (n = 1216), prior history CAD or revasculari..
.. zation (n = 992), and obstructive CAD (n = 1975) (Figure 1). Finally, a total
.. of 4644 patients were included in the current analysis. All study
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participants provided written informed consent and each of the study
sites’ institutional review boards approved the study protocol.

Clinical data and image acquisition

Study endpoint
The primary outcome of the current study was MACE, which was defined
as all-cause mortality (ACM) and myocardial infarction (MI). Follow-up
procedures were approved by all study centres’ institutional review
boards. Ascertainment of ACM and MI events was determined by direct/
telephone interview, as well as review of medical charts, and/or query of
the national medical database at each institution by a dedicated physician
and/or research nurse.

Statistical analysis
Continuous variables are expressed as mean ± standard deviation, and
categorical variables are reported as counts with proportions.
Continuous variables are compared using unpaired Student’s t-test and
categorical variables are compared using Pearson’s v2 test. The
Framingham risk score was calculated and categorized as low (<10%),
intermediate (10–20%), or high (>20%) risk groups.19 Cumulative MACE
incidence was assessed using the Kaplan–Meier method and compared
with log-rank test. Cox proportional hazard regression analysis was used
to calculate hazard ratio (HR) with 95% confidence interval (CI).
Multivariable analysis was adjusted for cardiovascular risk factors including age, gender, body mass index, hypertension, diabetes, dyslipidaemia,
smoking, and family history of CAD and extensive CAD. All statistical
analyses were performed using STATA (version 14; StataCorp, College
Station, TX, USA), and a P-value <0.05 was considered statistically
significant.

Results
The mean age of the study population was 56.7 ± 12.1 years and
54.8% were male. Baseline characteristics according to CCTA stenosis are shown in Table 1. There were 2579 (55.5%) and 2065
(44.5%) patients who had no and non-obstructive CAD by CCTA,
respectively. The prevalence of hypertension, diabetes, and dyslipidaemia were increased in patients with non-obstructive CAD. The
proportion of patients with family history of CAD and current
smoker did not differ between stenosis groups.
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Table 1

Baseline characteristics by CCTA stenosis
No CAD
Non-obstructive
(n 5 2579) CAD (n 5 2065)

P-value

.................................................................................................
Age (years)

53.3 ± 12.2

61.0 ± 10.5

<0.001

Male
BMI

1258 (48.9)
27.4 ± 5.2

1282 (62.1)
27.9 ± 5.2

<0.001
0.005

Hypertension

1110 (43.2)

1161 (56.6)

<0.001

Diabetes
Dyslipidaemia

286 (11.1)
1067 (41.7)

280 (13.6)
1188 (57.8)

0.010
<0.001

Current smoking

421 (16.5)

355 (17.3)

0.440

Family history of CAD
Framingham risk score

804 (31.6)
9.6 ± 7.8

609 (29.7)
14.3 ± 10.3

0.170
<0.001

1678 (65.8)

869 (42.5)

<0.001

Intermediate (10–20) 643 (25.2)
High (>20)
228 (8.9)

751 (36.7)
427 (20.9)

<0.001
<0.001

Low (<10)

Values are mean ± standard deviation or number (percentage).
BMI, body mass index; CAD, coronary artery disease; CCTA, coronary computed
tomography angiography.

Of the 2065 patients with non-obstructive CAD, 1767 (85.6%)
patients had proximal segment involvement. Patients with non-obstructive CAD with proximal involvement were older (P = 0.019)
and the prevalence of hypertension and dyslipidaemia were greater
than patients without proximal involvement (all P < 0.05, Table 2).
The proportion of male and patients with diabetes, current smoker
and family history did not differ between proximal involvement and
non-proximal CAD patients. The Framingham risk score was higher

Table 2 Baseline characteristics of patients with nonobstructive CAD according to proximal involvement
With
proximal
disease
(n 5 1767)

Without
proximal
disease
(n 5 298)

P-value

61.2 ± 10.6
1097 (62.2)

59.7 ± 10.5
185 (62.1)

0.019
0.981

.................................................................................................
Age (years)
Male
BMI

28.0 ± 5.2

27.5 ± 5.0

0.139

Hypertension
Diabetes

1021 (58.2)
244 (13.9)

140 (47.1)
36 (12.1)

<0.001
0.412

Dyslipidaemia

1041 (59.3)

147 (49.5)

0.002

Current smoking
Family history of CAD

300 (17.1)
526 (30.0)

55 (18.5)
83 (28.0)

0.563
0.465

Framingham risk score

14.5 ± 10.5

13.1 ± 9.1

0.039

Low (<10)
Intermediate (10–20)

729 (41.7)
647 (37.0)

140 (47.1)
104 (35.0)

0.077
0.518

High (>20)

374 (21.4)

53 (17.9)

0.167

Non-extensive CAD (SIS <_ 4) 1415 (80.1)
Extensive CAD (SIS > 4)
352 (19.9)

297 (99.7)
1 (0.3)

<0.001
<0.001

Values are mean ± standard deviation or number (percentage).
BMI, body mass index; CAD, coronary artery disease; SIS, segment involvement
score.
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Prior to coronary computed tomography (CT) scanning procedures,
baseline information for each patient were collected, including the
presence of traditional cardiac risk factors, age, sex, history of hypertension, diabetes mellitus, hyperlipidaemia, smoking status, early family
history of early CAD (father <55 or mother <65 years of age), and
prior history of CAD. CCTA was performed using multi-detector CT
scanners with more than 64 detector rows and following Society of
Cardiovascular Computed Tomography guidelines.18 CCTA was interpreted onsite for the presence of coronary atherosclerotic plaque,
based on a 16-segment modified SCCT coronary artery model.18
Lesions on CCTA were further categorized according to the severity
of stenosis as follows: 0% (no CAD) and 1–49% (non-obstructive
CAD). Proximal involvement was defined as any plaque present in
the left main (LM) or the proximal segment of the left anterior
descending artery (LAD), left circumflex artery (LCX), and right coronary artery (RCA). Extensive CAD was defined as a segment involvement score (SIS) >4.6

D. Han et al.
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Table 3

Incidence of MACE
Number
of
patients

Number
of MACE
(%)

Annualized
MACE rate
(95% CI)

.................................................................................................
Overall

4644

340 (7.3)

1.4 (1.3–1.6)

No CAD
Non-obstructive CAD

2579
2065

125 (4.9)
215 (10.4)

0.9 (0.8–1.1)
2.1 (1.8–2.4)

298

22 (7.4)

1.3 (0.9–2.0)

1767

193 (10.9)

2.2 (1.9–2.5)

Without proximal disease
With proximal disease

CAD, coronary artery disease; CI, confidence interval; MACE, major adverse cardiovascular events.
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Figure 2 Kaplan–Meier curve for MACE according to stenosis severity and proximal involvement. CAD, coronary artery disease.

Statin use information was available in 73% of the study population
(n = 3374). When further adjustment for the statin use in multivariate
Cox regression analysis, proximal involvement was still a significant
predictor of MACE (HR 2.25, 95% CI 1.60–3.18, P < 0.001;
Supplementary data online, Table S3).

Discussion
In this prospective observational multicentre registry, we demonstrated that the presence of non-obstructive plaque in proximal coronary segments was associated with a two-fold higher risk of MACE
compared to patients without CAD as assessed by CCTA, independent of plaque extent and conventional CAD risk factors.
Furthermore, patients with both extensive and proximal CAD had
greater risk of MACE compared to patients with either nonextensive or non-proximal non-obstructive CAD. Non-obstructive
CAD localized in the mid or distal segments did not significantly increase MACE risk when compared to patients with no CAD. The
current study findings suggest that the assessment of coronary plaque
location by CCTA may enhance the utility of CCTA to risk stratify
patients with non-obstructive CAD.
Prior angiographic studies have demonstrated that plaque rupture
and thrombotic occlusion tend to cluster in the proximal third of the
coronary arteries.9,10,20 In addition, the presence and severity of
CAD in the proximal coronary segments have shown to be strong
predictors of prognosis. In studies with patients who underwent coronary artery calcium (CAC) scan, the presence and high burden of
CAC in the LM are independently associated with increased mortality rate compared to other coronary arteries.21,22 In another study
from the Framingham Heart Study, the presence of CAC in the proximal coronary artery predicted major coronary heart disease events
after adjustment for cardiovascular risk factors and Agatston CAC
score.23 Several studies with CCTA have also demonstrated the
prognostic significance of proximal CAD, while those studies paid
more attention to risk in obstructive CAD.14–16
Prior efforts to improve risk stratification of non-obstructive CAD
by CCTA have mainly focused on characterizing the extent of
affected coronary segments by non-obstructive plaque. Lin et al.6
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in patients with proximal involvement. Extensive CAD (SIS > 4) was
observed in 19.9% of patients with proximal involvement, while was
only 0.3% (1/298) in non-proximal CAD patients.
During the median 5.2 years (interquartile range 4.1–6.0) of study
follow-up, 340 (7.3%) MACE occurred (195 ACM and 145 MI). The
annualized MACE rate was 0.9 (95% CI 0.8–1.1) and 2.1 (95% CI 1.8–
2.4) for the no CAD and non-obstructive CAD group (Table 3).
When patients with non-obstructive CAD were further stratified by
proximal involvement, the annualized MACE rate was 1.3 (95% CI
0.8–2.0) and 2.2 (95% CI 1.9–2.5) for non-obstructive CAD without
proximal involvement and with proximal involvement, respectively. In
Kaplan–Meier curve analysis, the presence of proximal involvement
was associated with higher rates of MACE when compared to
patients without proximal involvement (P = 0.033, Figure 2). In contrast, no significant difference in MACE rates were found between
patients with no CAD vs. patients with non-obstructive CAD without
proximal involvement (P = 0.122). Patients with non-obstructive
CAD that was both extensive (more than four segments) and
included proximal involvement had greater probability for MACE
compared to patients with non-obstructive CAD that was nonextensive but included proximal involvement or with non-extensive
and non-proximal involvement (log-rank P < 0.001 for trend, Figure 3).
In Cox regression analysis, the presence of any non-obstructive
CAD was associated with higher MACE risk compared to patients
with no apparent CAD (HR 2.24, 95% CI 1.79–2.81, P < 0.001). After
adjustment for conventional cardiovascular risk factors and the presence of extensive CAD, non-obstructive CAD with proximal involvement was a significant predictor of MACE (HR 1.90, 95% CI
1.47–2.45, P < 0.001; Table 4). In contrast, non-obstructive CAD
without proximal involvement did not significantly increase MACE
risk (HR 1.26, 95% CI 0.79–2.01, P = 0.339). When compared to nonobstructive non-proximal CAD, proximal involvement was associated with numerically increased MACE risk with borderline significance (HR 1.52, 95% CI 0.98–2.36, P = 0.060, Supplementary data
online, Table S1). When further stratified by type of event (ACM or
MI), non-obstructive CAD with proximal involvement significantly
increased the risk of both ACM and MI (P = 0.018 and 0.001, respectively; Supplementary data online, Table S2). Non-obstructive proximal involvement of the LM and the other three major epicardial
coronary arteries (proximal LAD, LCX, and RCA) were independently associated with increased MACE risk (Table 5, all P < 0.05).
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disease; MACE, major adverse cardiovascular events.

Table 4

Cox regression analysis
Univariate

.....................................................................
HR

95% CI

P-value

Multivariate

.....................................................................

HR

95% CI

P-value

....................................................................................................................................................................................................................
Clinical characteristics
Age (years)

1.05

1.04–1.05

<0.001

1.04

1.03–1.05

Male

0.97

0.78–1.21

0.784

1.04

0.83–1.31

0.731

BMI (>30 kg/m2)
Hypertension

1.71
1.67

1.38–2.13
1.33–2.08

<0.001
<0.001

1.88
1.21

1.50–2.36
0.95–1.53

<0.001
0.117

Diabetes

1.81

1.38–2.38

<0.001

1.48

1.11–1.96

0.007

Dyslipidaemia
Current smoking

0.82
1.28

0.65–1.02
0.98–1.67

0.069
0.067

0.64
1.45

0.51–0.80
1.11–1.91

<0.001
0.007

Family history of CAD

0.78

0.61–1.00

0.051

0.97

0.75–1.25

0.804

CCTA characteristics
SIS > 4

<0.001

2.31

0.71–3.12

<0.001

1.23

0.84–1.81

0.293

Non-obstructive CAD

2.24

1.79–2.81

<0.001

1.75

1.36–2.25

<0.001

Without proximal
With proximal

1.45
2.39

0.91–2.31
1.90–3.00

0.115
<0.001

1.26
1.90

0.79–2.01
1.47–2.45

0.339
<0.001

BMI, body mass index; CAD, coronary artery disease; CCTA, coronary computed tomography angiography; CI, confidence interval; HR, hazard ratio; SIS, segment involvement
score.

examined mortality risk in relation to the extent of non-obstructive
CAD in 2583 patients and found that the risk of mortality was significantly increased as the number of segments with non-obstructive plaques increased. In another study, Bittencourt et al.7 reported that the
presence of extensive non-obstructive disease, defined as SIS >4, was
associated with an increased rate of MACE events, whereas nonextensive non-obstructive CAD was not. Few prior studies demonstrated that assessing the number of proximal segments with any plaques or non-obstructive LM disease improved the prediction of

..
..
..
..
..
..
..
..
..
..
..
..
..
.

adverse cardiovascular outcomes.15,24,25 In addition, Weir-McCall
et al.26 reported the presence of non-obstructive LM disease was
associated with greater plaque progression and higher prevalence of
high-risk plaque compared to those without LM involvement.
However, these studies did not explore the prognostic significance of
proximal involvement in non-obstructive CAD. One study by
Mushtaq et al.27 reported that a detailed scoring system weighting
more risk in the LM, proximal LAD, and LCX was independently
associated with increased cardiovascular risk. Our findings confirm
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Figure 3 Kaplan–Meier curve for MACE according to extensive CAD and proximal involvement in non-obstructive CAD. CAD, coronary artery
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Prognostic significance of plaque location

Table 5 Cox regression analysisa according to location
of proximal coronary segments
95% CI

P-value

Any LM

1.38

1.11–1.71

0.004

Any proximal LAD
Any proximal LCX

1.56
1.41

1.30–1.88
1.16–1.72

<0.001
0.001

Any proximal RCA

1.47

1.21–1.79

<0.001

BMI, body mass index; CAD, coronary artery disease; CI, confidence interval; HR,
hazard ratio; LAD, left anterior descending artery; LCX, left circumflex artery;
LM, left main, RCA, right coronary artery.
a
Adjustment for age, BMI, sex, hypertension, diabetes, dyslipidaemia, smoking,
family history of CAD, and extensive CAD (SIS > 4).

and expand these prior observations by demonstrating the proximal
involvement of non-obstructive CAD was independently associated
with increased MACE risk. Furthermore, considering both extent
and proximal involvement of CAD provided an improved risk stratification in patients with non-obstructive CAD.
One of the benefits of CCTA is identifying the early stages of atherosclerotic disease within the coronary arteries, allowing to identify
patients who could benefit from aggressive preventive care and risk
factor modification. The recent long-term follow-up in the Scottish
COmputed Tomography of the HEART (SCOT-HEART) study demonstrated significant MACE reductions in the CCTA randomized
arm, coupled with increased prescription of statin and aspirin for
CCTA-visualized non-obstructive disease.28 In the current study,
there are heterogeneities in MACE risk in patients with non-obstructive CAD according to plaque location and extension. The
assessments of location and extent of plaque involvement are easy to
adopt in clinical practice and may allow improved risk stratification of
patients with non-obstructive CAD.

Limitations
Our study has few limitations. Due to the observed nature of the current study, we cannot discount the possibility of unmeasured confounding factors that might affect the clinical endpoints of this study.
The information regarding downstream pharmacological and/or
interventional management after CCTA was unavailable. Future studies investigating the impact of medication adjustment (e.g. aspirin, statin, and beta-blockers) on outcomes in patients with non-obstructive
CAD should be performed. The relatively small sample size of
patients with non-obstructive non-proximal CAD may cause our
results to be underpowered in detecting differences in prognosis
according to proximal involvement in non-obstructive CAD. The
clinical endpoint examined was ACM and clinically recorded MI.
Cardiovascular mortality which would be expected to be more
strongly associated with the atherosclerotic burden was not available
in this population. Despite this, the use of all-cause death may lower
the possibility of bias due to misreporting or misclassification of
death, which can often be the case when utilizing cause-specific mortality.29 When stratified by type of event, proximal involvement in
non-obstructive CAD was a significant predictor of MI events which
are more specifically related to atherosclerotic burden. It is possible
that MI events occurred in small mid or distal segments may not have
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HR

.................................................................................................

..
.. been recorded as a significant clinical event. This may explain, in part,
.. our observation of a similar MACE rates between patients with non..
.. proximal non-obstructive CAD vs. with no CAD.
..
..
..
.. Conclusion
..
..
.. Independent of the extent of coronary plaque, proximal coronary in.. volvement was associated with increased MACE risk in patients with
..
.. non-obstructive CAD. Localization of coronary plaques by CCTA
.. may provide additional prognostic value for MACE risk prediction in
..
.. patients with non-obstructive CAD.
..
..
..
.. Supplementary data
..
..
.. Supplementary data are available at European Heart Journal - Cardiovascular
.. Imaging online.
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